Featured
-
-
Translational Therapeutics
| Open AccessTumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
- J Murray
- , H Thomas
- & N J Curtin
-
Translational Therapeutics
| Open AccessPrediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
- M Wilbaux
- , E Hénin
- & B You
-
Translational Therapeutics
| Open AccessAnticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1
- Y Akashi
- , T Oda
- & N Ohkohchi
-
Molecular Diagnostics
| Open AccessGenistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells
- H Hirata
- , Y Hinoda
- & R Dahiya
-
Clinical Study
| Open AccessEfficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
- T E Hutson
- , R M Bukowski
- & R J Motzer
-
Short Communication
| Open AccessInhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations
- S Hu
- , R H J Mathijssen
- & A Sparreboom
-
Clinical Study
| Open AccessPazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study
- P Hamberg
- , M J Boers-Sonderen
- & S Sleijfer
-
Translational Therapeutics
| Open AccessSulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation
- Y Zhang
- , S Dayalan Naidu
- & A T Dinkova-Kostova
-
Clinical Study
| Open AccessSLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours
- A Khatri
- , B W Williams
- & M N Kirstein
-
Translational Therapeutics
| Open Accessp53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
- J Sonnemann
- , C Marx
- & J F Beck
-
Clinical Study
| Open AccessCYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer
- N Yamamoto
- , H Murakami
- & K Nakagawa
-
Clinical Study
| Open AccessA dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
- A Adenis
- , I Ray-Coquard
- & N Penel
-
Clinical Study
| Open AccessA study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
- A Gibb
- , A Greystoke
- & J Radford
-
Clinical Study
| Open AccessPhase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
- Y-K Kang
- , C Yoo
- & M-H Ryu
-
Clinical Study
| Open AccessMean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
- F Joulain
- , I Proskorovsky
- & E Van Cutsem
-
Clinical Study
| Open AccessTrabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
- A L Cesne
- , I Judson
- & J-Y Blay
-
Clinical Study
| Open AccessHigher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)
- S G Louie
- , B Ely
- & C D Blanke
-
Short Communication
| Open AccessThe interaction between prognostic and pharmacodynamic biomarkers
- L Bouranis
- , M Sperrin
- & A G Renehan
-
Clinical Study
| Open AccessPhase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
- H K Ahn
- , J Y Choi
- & Y S Park
-
Clinical Study
| Open AccessS-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
- S Y Kim
- , Y S Hong
- & K H Jung
-
Clinical Study
| Open AccessA phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer
- J M Sun
- , J R Kim
- & K Park
-
Clinical Study
| Open AccessPhase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
- T Hoehler
- , G von Wichert
- & U T Hacker
-
Clinical Study
| Open AccessA multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
- D W Bowles
- , W W Ma
- & A Jimeno
-
Clinical Study
| Open AccessA phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
- P A Cassier
- , A Lefranc
- & J-Y Blay
-
Clinical Study
| Open AccessReporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials
- G A Freeman
- , J Kimmelman
- & J G Monzon
-
Molecular Diagnostics
| Open AccessPazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
- M Santoni
- , C Amantini
- & G Santoni
-
Translational Therapeutics
| Open AccessTumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model
- J J Arcaroli
- , K S Quackenbush
- & W A Messersmith
-
Translational Therapeutics
| Open AccessVEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
- P Orlandi
- , A Fontana
- & G Bocci
-
Genetics and Genomics
| Open AccessDUSP6 regulates drug sensitivity by modulating DNA damage response
- T V Bagnyukova
- , D Restifo
- & I Astsaturov
-
Translational Therapeutics
| Open AccessSynergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
- J Wan
- , T Liu
- & W Li
-
Translational Therapeutics
| Open AccessAssociation between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
- J Mendoza
- , J Martínez
- & L A Herrera
-
Molecular Diagnostics
| Open AccessAutophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma
- J Shen
- , H Zheng
- & P Zhao
-
Letter to the Editor
| Open AccessComment on ‘The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer‘
- D Kitchen
- , M O'Brien
- & J Stebbing
-
Molecular Diagnostics
| Open AccessPharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
- A Loganayagam
- , M Arenas Hernandez
- & A M Marinaki
-
Clinical Study
| Open AccessAromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series
- F Zagouri
- , T N Sergentanis
- & R Bartsch
-
Translational Therapeutics
| Open AccessMelatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells
- V Martín
- , A M Sanchez-Sanchez
- & C Rodriguez
-
Clinical Study
| Open AccessCombination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
- L W-C Chow
- , B Xu
- & I Bondarenko
-
Clinical Study
| Open AccessEverolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
- I Ray-Coquard
- , L Favier
- & E Pujade-Lauraine
-
Clinical Study
| Open AccessSunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
- M D Michaelson
- , A X Zhu
- & A B Schwarzberg
-
Clinical Study
| Open AccessEfficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
- G Pfeiler
- , H Stöger
- & M Gnant
-
Translational Therapeutics
| Open AccessIdentification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
- S M Tijono
- , K Guo
- & L-M Ching
-
Clinical Study
| Open AccessA randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea
- V M Coyle
- , D Lungulescu
- & R H Wilson
-
Molecular Diagnostics
| Open AccessSingle-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
- B Beuselinck
- , A Karadimou
- & S Oudard
-
Clinical Study
| Open AccessA first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours
- M A Warso
- , J M Richards
- & T K Das Gupta
-
Clinical Study
| Open AccessAdjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)
- Y-K Kang
- , H-M Chang
- & B S Kim
-
Translational Therapeutics
| Open AccessMarked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1
- M Mimeault
- , S L Johansson
- & S K Batra
-
Clinical Study
| Open AccessBiomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- D W Miles
- , S L de Haas
- & S J Scherer
-
Clinical Study
| Open AccessDocetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
- N C Tebbutt
- , M M Parry
- & V J Gebski
-
Short Communication
| Open AccessPhase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer
- V Heinemann
- , M P Ebert
- & S Boeck